Early real-world experience with the 2024 McDonald criteria suggests a meaningful increase in multiple sclerosis (MS) diagnoses, driven largely by recognition of optic nerve involvement and reclassification of radiologically isolated syndrome. Hear from Dr. Aaron Miller as he reviews emerging evidence, explains how these updates are reshaping diagnostic pathways, and addresses practical challenges in implementation. Dr. Miller is the Medical Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis and a Professor of Neurology at the Icahn School of Medicine at Mount Sinai in New York. He also spoke about this topic at the 2026 American Academy of Neurology (AAN) Annual Meeting.
Applying the 2024 McDonald Criteria: Real-World Impacts on MS Diagnosis

Announcer:
You’re listening to NeuroFrontiers on ReachMD. On this episode, we’ll hear from Dr. Aaron Miller, the Medical Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis and a Professor of Neurology at the Icahn School of Medicine at Mount Sinai in New York. He’ll be discussing real-world applications of the updated McDonald Diagnostic Criteria for multiple sclerosis, which he spoke about at the 2026 American Academy of Neurology Annual Meeting. Here’s Dr. Miller now.
Dr. Miller:
There are a lot of people we can pick up who we wouldn't have diagnosed in 2017. So, where are we in real-world experience so far? Well, there’s only been a couple of publications so far, but they are already very encouraging. So far, it looks like there's a very substantial increase in the number of people who can be diagnosed with MS using the 2024 criteria compared to 2017, and most of those are accounted for either by the presence of the optic nerve involvement, which didn't count before, or they're people who we would've previously classified as radiologically isolated syndrome, and it now can be called MS.
In terms of practitioners in the community wanting to use these criteria, although we don't have a specific algorithm for how you should proceed because different centers or practices will have different tools available—for example, the advanced imaging techniques are not generally available at the present time—we anticipate that within the next couple of years, most of the major MRI manufacturers will have protocols approved that include the right sequences for good detection of central veins or PRLs. But most centers might not have that at the moment. Some centers might not have access to visual evoked potentials, for example, and there are some parts of the world where you might not even be able to get an MRI. But it would be very rare to diagnose MS when you do not have MRIs.
So, because of this variability, we don't have a specific algorithm, but I would refer our listeners to the National MS Society, which has materials on the new McDonald criteria on the website, including some very good flow diagrams that show you the criteria that are needed in each of these circumstances. In addition, the National MS Society, around the time of the academy meeting, will be launching an e-learning module, which is an exercise that practitioners can utilize to help them become familiar and comfortable with the 2024 McDonald criteria.
Announcer:
That was Dr. Aaron Miller sharing insights on how we can implement the 2024 McDonald Diagnostic Criteria in multiple sclerosis care. To access this and other episodes in our series, visit NeuroFrontiers on ReachMD.com, where you can Be Part of the Knowledge. Thanks for listening!
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
audioUpdates in MS Care: Key Topics at AAN 2026
Show more
audioProactive Pregnancy Planning and Reproductive Care in MS
Show more
audioAdvancing Pediatric MS Care: Insights from AAN 2026
Show more
text-as-primaryFamily Planning in Patients with Multiple Sclerosis
Show more
text-as-primaryDepression as a Signal of MS Progression
Show more
text-as-primaryEmerging Serum microRNAs as Early Signals in MS
Show more
Overview
Early real-world experience with the 2024 McDonald criteria suggests a meaningful increase in multiple sclerosis (MS) diagnoses, driven largely by recognition of optic nerve involvement and reclassification of radiologically isolated syndrome. Hear from Dr. Aaron Miller as he reviews emerging evidence, explains how these updates are reshaping diagnostic pathways, and addresses practical challenges in implementation. Dr. Miller is the Medical Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis and a Professor of Neurology at the Icahn School of Medicine at Mount Sinai in New York. He also spoke about this topic at the 2026 American Academy of Neurology (AAN) Annual Meeting.
audioUpdates in MS Care: Key Topics at AAN 2026
Show more
audioProactive Pregnancy Planning and Reproductive Care in MS
Show more
audioAdvancing Pediatric MS Care: Insights from AAN 2026
Show more
text-as-primaryFamily Planning in Patients with Multiple Sclerosis
Show more
text-as-primaryDepression as a Signal of MS Progression
Show more
text-as-primaryEmerging Serum microRNAs as Early Signals in MS
Show more
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?






